Core Viewpoint - The controversy surrounding the collagen content in the product "Kefumei" from Giant Biological has raised significant consumer and investor concerns, with ongoing debates about the accuracy of testing methods and results [1][10]. Group 1: Testing Results - Giant Biological confirmed that the "Kefumei Human-like Recombinant Collagen Essence" contains recombinant collagen, with content levels greater than 0.1% as per third-party testing [2][10]. - The testing utilized two methods: LC-MS/MS for qualitative analysis and the Biuret method for quantitative analysis, with results showing collagen content of 0.2%, 0.22%, and 0.2% across three batches [2][8]. - A subsequent test on one batch indicated a collagen content of 0.17%, confirming that the product meets the stated requirements [8][9]. Group 2: Consumer Concerns and Responses - The initial claim by beauty blogger "Big Mouth Doctor" suggested that the actual collagen content was only 0.0177%, leading to widespread skepticism about the product's integrity [10][11]. - Giant Biological emphasized that there is no misleading advertising and that the product has been properly tested, countering claims of "quietly delisting" the product due to sales issues [10][11]. - The company expressed concern over consumer anxiety caused by misinformation and reiterated its commitment to transparency and product integrity [10][11]. Group 3: Industry Reactions - Huaxi Biological publicly supported the claims made by "Big Mouth Doctor," indicating that they have conducted their own evaluations and testing of the product [11][14]. - Huaxi Biological criticized Giant Biological for alleged unethical marketing practices and indicated readiness to engage in a public discourse regarding product integrity [14][15].

Core Viewpoint - Lin Qingxuan, a high-end domestic skincare brand, has submitted its IPO application to the Hong Kong Stock Exchange, marking its ambition to enter the public market after 23 years of establishment [1] Company Overview - Founded in 2003 by Sun Chunlai, Lin Qingxuan has gained popularity among young consumers through its unique marketing strategies, including the distribution of handmade essential oil soaps [1] - The brand claims to rank first among domestic high-end skincare brands in China based on retail sales for 2024, and it is the only domestic brand among the top 15 high-end skincare brands in China [1] Financial Performance - Lin Qingxuan's revenue for the years 2022 to 2024 was reported as 691 million yuan, 805 million yuan, and 1.209 billion yuan respectively [2] - The company's profit over the past three years showed significant fluctuations, with figures of -5.93 million yuan, 84.5 million yuan, and 186 million yuan, indicating a transition from losses to profitability [2] Market Trends - The high-end skincare market in China has grown from 749 billion yuan in 2019 to an expected 1,144 billion yuan in 2024, with projections to reach 2,185 billion yuan by 2029 [3] - The market for high-end anti-wrinkle and firming products is projected to grow from 594 billion yuan in 2024 to 1,555 billion yuan by 2029, with a compound annual growth rate (CAGR) of 21.2% [3] Product Strategy - Lin Qingxuan has focused on essential oil skincare, with its signature Camellia Oil leading sales, accounting for 31.5%, 35.3%, and 37% of total revenue over the past three years [5] - The company has also introduced new products, with facial creams becoming a significant revenue contributor, increasing from 13.7% of total revenue in 2022 to 15.7% in 2024 [5] Brand Positioning - Despite its focus on essential oils, Lin Qingxuan struggles to position itself as a "high-end" brand compared to international competitors like La Mer and Sisley [6] - The average price per milliliter for Lin Qingxuan's Camellia Oil is approximately 27.3 yuan, significantly lower than that of its high-end counterparts [6] Distribution Channels - As of 2024, Lin Qingxuan operates 506 stores nationwide, with a significant presence in new first-tier and third-tier cities [7] - The company has seen a shift in sales channels, with online sales projected to account for 59.1% of revenue in 2024, compared to 40.8% from offline channels [6] Challenges Ahead - Lin Qingxuan's primary market is in new first-tier and third-tier cities, but competition from international brands like Lancôme and Estée Lauder poses challenges for capturing the high-end market segment [8] - The company's R&D expenditures from 2022 to 2024 were 21.1 million yuan, 19.7 million yuan, and 30.4 million yuan, representing a moderate investment level relative to its revenue base [8]

一直想写一篇关于定价和促销的文章，系统的阐述我们的理解。可能会有读者觉得这是两个不同的话题。但我们认为：促销设计可以视为消费品定价的延 伸，即在定价时就可以将一部分促销成本设计在内，以保持产品价格的相对稳定。这有点违背现在市场流行的常识，下文中我们会尝试阐述清晰，希望可 以给到大家更多的思考和启发。 由于定价的问题涉及庞杂，文章内容会比较长，我们会努力拆分为更容易理解的模块，提高阅读的舒适感。如有谬误之处，还请大家多多指点。 一、消费品的价值结构 很多人会说：用户购买消费品，买的是产品价值。我们认为这是产品定价的入口，如果不能很好的理解消费品的价值结构，是很难做好定价的。我们也曾 尝试通过马斯洛需求层次帮助理解，但始终有些困惑，直到系统的学习了《符号学》才豁然开朗。下文也会引入一部分的相关概念帮助阐述和理解。 1. 产品价值&马斯洛需求层次 关于消费产品的价值，行业内的分类标准比较庞杂，最常见的是功能价值/精神价值，其他大多是在这个基础上演化出来的新名词。有些创业者的梦想是 做个中高端品牌，但我们都很清楚，仅仅依靠功能价值是不够的，必须要塑造品牌的精神价值。但精神价值是如何构成的？如何塑造的？鲜有文章说的清 ...

证券研究报告·行业跟踪周报·商贸零售 证券分析师 张家璇 商贸零售行业跟踪周报 林清轩正式递表港交所，国产高端护肤开启 资本化新篇章 增持（维持） [Table_Tag] [投资要点 Table_Summary] 2025 年 06 月 04 日 证券分析师 吴劲草 执业证书：S0600520090006 wujc@dwzq.com.cn 证券分析师 石旖瑄 执业证书：S0600522040001 shiyx@dwzq.com.cn 执业证书：S0600520120002 zhangjx@dwzq.com.cn 证券分析师 阳靖 执业证书：S0600523020005 yangjing@dwzq.com.cn 证券分析师 郗越 执业证书：S0600524080008 xiy@dwzq.com.cn 研究助理 王琳婧 执业证书：S0600123070017 wanglj@dwzq.com.cn 行业走势 -14% -8% -2% 4% 10% 16% 22% 28% 34% 40% 46% 2024/6/3 2024/10/1 2025/1/29 2025/5/29 商贸零售 沪深300 相关研究 《酒店集团业 ...

Summary of the Conference Call Transcript Company Overview - **Company**: 贝泰妮 (Betaini) - **Industry**: Consumer Goods, specifically skincare and beauty products Key Points and Arguments 1. **Profitability Goals**: The company aims for a double-digit net profit margin by 2025, up from 8.8% in 2024, supported by a targeted 3% increase in gross margin, efficiency improvements, and operational leverage [1][4] 2. **Revenue Targets**: - Main brand, 薇诺娜 (Winona), is expected to achieve single-digit revenue growth, focusing on product reform and promotional control [1][4] - Emerging brands are projected to maintain growth momentum, with 薇诺娜宝贝 (Winona Baby) targeting over 30% growth, 瑗科缦 (Yuan Keman) over 100%, and 贝芙汀 (Beifutin) aiming for 50 million yuan [1][4] 3. **Quarterly Performance**: The second quarter shows improvement, with a strong start to the 6.18 shopping event, reporting a 20-30% increase in GMV through live streaming channels and a 30-40% increase on Douyin [1][4] 4. **Inventory Management**: Inventory balances improved, with figures of 556 million yuan and 612 million yuan for Q1 2025 and FY2024 respectively, down 34% and 32% from FY2023 [1][4] 5. **OTC Channel Expansion**: Sales in the OTC channel are recovering, with a projected 10% growth in sales for approximately 129,000 OTC pharmacies in 2024 [1][4] 6. **Financial Forecasts**: - Revenue is expected to grow from 5.736 billion yuan in FY24 to 6.196 billion yuan in FY25, with a compound annual growth rate (CAGR) of 10% from 2025 to 2027 [1][9] - Adjusted net profit is projected to increase from 503 million yuan in FY24 to 654 million yuan in FY25 [1][8] 7. **Market Position**: Winona is the largest efficacy skincare brand in China, holding a 20% market share, outperforming competitors like 理肤泉 (La Roche-Posay) and 修丽可 (SkinCeuticals) [1][9] 8. **Valuation**: The target price is set at 66 yuan, corresponding to a 35x 12-month forward P/E ratio, based on a discounted cash flow analysis [1][14] Additional Important Information - **Risks**: - Downside risks include potential failure in brand expansion, high traffic costs, intensified competition, and increased regulatory scrutiny on efficacy skincare advertising [1][16] - Upside catalysts include better-than-expected performance of new products and successful acquisitions [1][16] - **Stock Performance**: The stock price as of May 28, 2025, is 45.29 yuan, with a target price of 66.00 yuan by December 2025 [2][22] This summary encapsulates the essential insights from the conference call, highlighting the company's strategic direction, financial targets, market positioning, and associated risks.

Core Viewpoint - The public dispute regarding the content of recombinant collagen in the product "Collagen Stick" from the brand Kefu Mei, owned by Giant Biological (02367.HK), has intensified, with accusations of misleading information about the actual collagen content [1][3]. Group 1: Company Response and Actions - Giant Biological received an apology from the testing agency used by the beauty blogger "Big Mouth Doctor" (Hao Yu) on May 30, and the company has sent products to multiple testing institutions for compliance checks [2][4]. - The company claims that multiple tests have shown collagen content greater than 0.1%, adhering to the standards set by the Chinese Pharmacopoeia [4]. - Giant Biological clarified that the rumors about the product "Collagen Stick 1.0" being taken off the shelves are false, stating it was a normal product iteration that began in April [6]. Group 2: Industry Context and Competitor Involvement - The controversy has drawn attention from competitors, notably Huaxi Biological, which publicly supported the claims made by "Big Mouth Doctor" and offered to assist in testing and regulatory communication [10]. - Huaxi Biological has criticized the overhyped claims surrounding recombinant collagen, suggesting that the industry is experiencing inflated expectations without sufficient scientific backing [13]. - The financial performance of Huaxi Biological has been declining, with a reported revenue of 5.371 billion in 2024, down 11.61% year-on-year, and a significant drop in net profit [13]. Group 3: Financial Performance of Giant Biological - Giant Biological has shown steady revenue growth from 1.19 billion in 2020 to 5.539 billion in 2024, with net profit increasing from 826 million to 2.062 billion during the same period [7]. - The Kefu Mei brand is a significant contributor to Giant Biological's revenue, accounting for 82% of total income in 2024, with a reported revenue of 4.542 billion [7]. - Concerns have been raised about the potential impact of the ongoing controversy on the company's performance during the critical 618 e-commerce promotion period [7].

林清轩业绩的快速增长很大程度得益于精华类明星单品的带动。光是精华油产品在2024年就贡献了4.48亿元的收 入，占总收入37%，在所有产品品类中占比最大，而这一比例前两年分别为31.5%和35.3%，呈现明显的上升趋 势。林清轩在招股书中提到：我们产品组合的核心是标志性的山茶花精华油，截至2024年12月31日，已累计销售 逾3000万瓶，根据灼识谘询的数据，按全渠道总零售额计自 2014年以来连续11年在所有面部精华油产品中稳居全 国榜首。该产品同时也在中国面部精华油品类中唯一连续8年零售额超过人民币1亿元的产品。 美妆赛道似乎在资本市场迎来回暖迹象。继毛戈平成功上市后，5月29日，上海林清轩生物科技股份有限公司（以 下简称"林清轩"）向港交所递交招股书，正式开启上市流程。凭借"山茶花精华油"这一明星单品切入国内高端护 肤赛道，林清轩在2024年实现营收12.1亿元，经调整后的净利润为2亿元，虽然营收和净利润并不算高，但毛利率 却高达82.5%。 林清轩近年加码布局线上渠道，业绩增长显著，但营销费用也连年上升，这几乎是所有头部国货美妆品牌的共性 问题。目前国内高端护肤市场大部分被国际大牌占领，作为国货美妆中 ...

Group 1 - The core viewpoint of the article highlights the dual nature of celebrity endorsements in brand marketing, where they can drive sales but also pose significant risks to brand reputation [1] - The brand endorsement market is expected to grow in 2024, with 1,222 brands announcing endorsements, an 11% increase from the previous year [2] - Top-tier celebrities are commanding endorsement fees exceeding 10 million yuan, equivalent to the annual net profit of many small to medium-sized enterprises [2] Group 2 - The case of the brand Perlayah, which saw a significant increase in exposure and interaction after announcing a partnership with celebrity Yi Yang Qianxi, illustrates the potential for immediate sales impact through celebrity endorsements [2][4] - The gum category has shown a remarkable sales growth rate of 38.89% in 2024, indicating a strong market performance [5] - The top three brands in the gum market, Stride, Green Arrow, and Yida, have increased their market share from 88% in 2023 to 92% in 2024, with each brand's growth rate exceeding 20% [6] Group 3 - The endorsement of the youth group "Times Youth" by Stride led to a 23.6% increase in sales after the announcement, demonstrating the strong influence of celebrity endorsements on consumer purchasing decisions [8] - Stride's market share surged by 8.7 percentage points in April, significantly outperforming a competing brand that saw a decline [10] - The social media engagement from the youth demographic contributed 72% of Stride's brand voice, indicating a successful alignment with the target audience [12] Group 4 - The article discusses the trend of brands utilizing non-human endorsements, such as animals and self-created IPs, to mitigate risks associated with celebrity endorsements [15][30] - The use of virtual digital personas for brand endorsements is on the rise, with examples of successful collaborations with beauty brands [40] - Brands are increasingly adopting multi-dimensional endorsement strategies to diversify risk and maximize brand communication effectiveness [51]

Core Viewpoint - The public relations battle between Huaxi Biological and Juzhi Biological has led to a significant market value loss for Juzhi Biological, amounting to 17.4 billion yuan in just 10 days [4]. Group 1: Public Relations Battle - Huaxi Biological publicly criticized the capital market's behavior of favoring collagen while disparaging hyaluronic acid, directly naming Juzhi Biological and several brokerage firms [3][4]. - Juzhi Biological's market value dropped from 90.9 billion yuan to 73.5 billion yuan within 10 days, a decrease of 17.4 billion yuan [4]. - The negative publicity may impact consumer sentiment and Juzhi Biological's performance during the upcoming 618 promotional event [4]. Group 2: Controversial Testing Methods - The primary controversy revolves around the testing methods used to assess the collagen content in Juzhi Biological's products [5][6]. - A beauty blogger claimed that the actual collagen content in Juzhi Biological's product was only 0.0177%, significantly below the stated standard of ≥0.1% [9]. - Juzhi Biological defended its testing methods, stating that the blogger's approach lacked industry standards and that they were involved in formulating these standards [11]. Group 3: Timeline of Events - On May 17, Huaxi Biological published a critical article targeting Juzhi Biological and brokerage firms [18]. - Juzhi Biological did not respond initially, leading to perceptions of a "pillow fight" in the public relations battle [18]. - The timeline of events suggests a coordinated effort by the blogger to raise questions about Juzhi Biological's products, particularly before the 618 sales event [22][23]. Group 4: Industry Implications - The incident serves as a cautionary tale for other beauty and skincare brands regarding the importance of protecting their core assets, particularly product ingredients and their efficacy [33]. - Companies are urged to establish robust standards and testing methods to safeguard against potential public relations crises [34]. - The need for a credible third-party testing framework is emphasized, as the absence of such standards can lead to consumer distrust and brand damage [30].

Core Insights - Morgan Stanley reported that during the 618 promotional period from May 13 to 26, 2023, promotional efforts varied significantly among brands, with Proya leading in Tmall beauty and Caitang ranking first in Douyin makeup [1][5] Tmall Rankings - Proya maintained the top position in Tmall beauty rankings during the 618 event, with L'Oreal Paris and Estee Lauder following in the top three [2] - Comfy, a brand under Giant Bio, ranked 3rd on May 13, dropped to 9th on May 15, and fell to 12th from May 16 to 26 in Tmall beauty rankings [1][6] Douyin Rankings - In Douyin makeup, Caitang ranked first, while Comfy's performance fluctuated, indicating a preference for balancing sales growth and profit margins rather than pursuing high rankings [1][5] - High-end skincare brands showed increased focus on Douyin, with seven brands entering the top ten during the promotional period [5] Comfy Brand Insights - Comfy's initial high rankings during e-commerce shopping festivals tend to decline, a pattern observed in previous events like Double 11 [1][6] - The brand's strategy includes collaborating with less promotional-driven key opinion leaders (KOLs) and limiting supply on heavily discounted packages [6] - Recent consumer concerns regarding Comfy products on social media may impact consumer confidence, although the company is expected to address these issues with independent testing results [6] Market Outlook - Morgan Stanley estimates that the recent decline in Giant Bio's stock price to a forward P/E ratio of approximately 22x reflects the market's absorption of some earnings downside risks from consumer feedback [7] - Despite short-term uncertainties, Morgan Stanley maintains a buy rating and advises investors to build long-term positions during stock price weaknesses [7]